Mergers & Acquisitions Mergers & Acquisitions

Comment: New transatlantic regulatory working group on pharma deals may help harmonize reviews while bringing 'aggressive' approach

By Natalie McNelis and Flavia Fortes
  • 16 Mar 2021 15:50
  • 25 Mar 2021 09:46
A new transatlantic working group for mergers in the pharmaceutical sector will provide an opportunity to build on existing cooperation among regulators in the US, UK, Canada and the European Union to help harmonize analysis, which has sometimes diverged in recent global deals. The unified process is good news for parties, but

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Natalie McNelis

Senior Correspondent

Natalie McNelis covers mergers for MLex in Brussels. Before joining MLex in 2017, she spent 20 years as an international trade and competition lawyer in law firms including Stibbe and WilmerHale. Natalie has a BA in English from Mount Holyoke College, a JD from Harvard Law School and an LLM in EU law from KU Leuven. She is admitted to the bar in New York.

Flavia Fortes

Global Head of Mergers

Flavia writes about merger control, antitrust enforcement and litigation in the U.S. and Brazil. Before joining MLex, Flavia worked as an Antitrust Consultant in the Federal Trade Commission's Office of International Affairs and as a Research Fellow for the American Antitrust Institute. She has written on the intersection of antitrust law and intellectual property law in technology-driven and innovative markets.

Discover MLex

Stay on top of global regulatory developments


Latest News